Five-year experience of human papillomavirus DNA and papanicolaou test cotesting

Walter Kinney, Philip E. Castle, Barbara Fetterman, Nancy Poitras, Thomas Lorey, Ruth Shaber

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

OBJECTIVE:: To estimate the 5-year age group-specific test positives for Pap tests and human papillomavirus (HPV) testing in a large, general screening population of women 30 and older. METHODS:: Using data from Kaiser Permanente Northern California, a large health maintenance organization that introduced cotesting in 2003, we evaluated the cotesting results overall and by 5-year age groups. Women (n=580,289) who opted for and underwent cotesting (n cotests=812,598) between January 2003 and April 2008 were included in the analysis. Pap tests interpreted as atypical squamous cells of undetermined significance (ASC-US) or more severe were considered to be positive. Women were tested for carcinogenic HPV using an assay approved by the U.S. Food and Drug Administration. Binomial exact 95% confidence intervals (CIs) were calculated. RESULTS:: Overall, 6.27% (95% CI 6.21-6.32%) of cotests were carcinogenic HPV positive, and only 3.99% (95% CI 3.94-4.03%) cotests had normal cytology and were carcinogenic HPV positive. By comparison, 5.18% (95% CI 5.13-5.23%) of cotests had ASC-US or more severe cytology, and 2.87% (95% CI 2.84-2.91%) of cotests had ASC-US or more severe cytology and were carcinogenic HPV negative. CONCLUSION:: In a general screening population, concerns about excessive HPV test positives among women aged 30 years and older are not borne out.

Original languageEnglish (US)
Pages (from-to)595-600
Number of pages6
JournalObstetrics and Gynecology
Volume113
Issue number3
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Human Papillomavirus DNA Tests
Papanicolaou Test
Confidence Intervals
Cell Biology
Age Groups
Health Maintenance Organizations
United States Food and Drug Administration
Population

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Five-year experience of human papillomavirus DNA and papanicolaou test cotesting. / Kinney, Walter; Castle, Philip E.; Fetterman, Barbara; Poitras, Nancy; Lorey, Thomas; Shaber, Ruth.

In: Obstetrics and Gynecology, Vol. 113, No. 3, 03.2009, p. 595-600.

Research output: Contribution to journalArticle

Kinney, Walter ; Castle, Philip E. ; Fetterman, Barbara ; Poitras, Nancy ; Lorey, Thomas ; Shaber, Ruth. / Five-year experience of human papillomavirus DNA and papanicolaou test cotesting. In: Obstetrics and Gynecology. 2009 ; Vol. 113, No. 3. pp. 595-600.
@article{cd9b1717dfa144edbec460d6c6238693,
title = "Five-year experience of human papillomavirus DNA and papanicolaou test cotesting",
abstract = "OBJECTIVE:: To estimate the 5-year age group-specific test positives for Pap tests and human papillomavirus (HPV) testing in a large, general screening population of women 30 and older. METHODS:: Using data from Kaiser Permanente Northern California, a large health maintenance organization that introduced cotesting in 2003, we evaluated the cotesting results overall and by 5-year age groups. Women (n=580,289) who opted for and underwent cotesting (n cotests=812,598) between January 2003 and April 2008 were included in the analysis. Pap tests interpreted as atypical squamous cells of undetermined significance (ASC-US) or more severe were considered to be positive. Women were tested for carcinogenic HPV using an assay approved by the U.S. Food and Drug Administration. Binomial exact 95{\%} confidence intervals (CIs) were calculated. RESULTS:: Overall, 6.27{\%} (95{\%} CI 6.21-6.32{\%}) of cotests were carcinogenic HPV positive, and only 3.99{\%} (95{\%} CI 3.94-4.03{\%}) cotests had normal cytology and were carcinogenic HPV positive. By comparison, 5.18{\%} (95{\%} CI 5.13-5.23{\%}) of cotests had ASC-US or more severe cytology, and 2.87{\%} (95{\%} CI 2.84-2.91{\%}) of cotests had ASC-US or more severe cytology and were carcinogenic HPV negative. CONCLUSION:: In a general screening population, concerns about excessive HPV test positives among women aged 30 years and older are not borne out.",
author = "Walter Kinney and Castle, {Philip E.} and Barbara Fetterman and Nancy Poitras and Thomas Lorey and Ruth Shaber",
year = "2009",
month = "3",
doi = "10.1097/AOG.0b013e3181996ffa",
language = "English (US)",
volume = "113",
pages = "595--600",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Five-year experience of human papillomavirus DNA and papanicolaou test cotesting

AU - Kinney, Walter

AU - Castle, Philip E.

AU - Fetterman, Barbara

AU - Poitras, Nancy

AU - Lorey, Thomas

AU - Shaber, Ruth

PY - 2009/3

Y1 - 2009/3

N2 - OBJECTIVE:: To estimate the 5-year age group-specific test positives for Pap tests and human papillomavirus (HPV) testing in a large, general screening population of women 30 and older. METHODS:: Using data from Kaiser Permanente Northern California, a large health maintenance organization that introduced cotesting in 2003, we evaluated the cotesting results overall and by 5-year age groups. Women (n=580,289) who opted for and underwent cotesting (n cotests=812,598) between January 2003 and April 2008 were included in the analysis. Pap tests interpreted as atypical squamous cells of undetermined significance (ASC-US) or more severe were considered to be positive. Women were tested for carcinogenic HPV using an assay approved by the U.S. Food and Drug Administration. Binomial exact 95% confidence intervals (CIs) were calculated. RESULTS:: Overall, 6.27% (95% CI 6.21-6.32%) of cotests were carcinogenic HPV positive, and only 3.99% (95% CI 3.94-4.03%) cotests had normal cytology and were carcinogenic HPV positive. By comparison, 5.18% (95% CI 5.13-5.23%) of cotests had ASC-US or more severe cytology, and 2.87% (95% CI 2.84-2.91%) of cotests had ASC-US or more severe cytology and were carcinogenic HPV negative. CONCLUSION:: In a general screening population, concerns about excessive HPV test positives among women aged 30 years and older are not borne out.

AB - OBJECTIVE:: To estimate the 5-year age group-specific test positives for Pap tests and human papillomavirus (HPV) testing in a large, general screening population of women 30 and older. METHODS:: Using data from Kaiser Permanente Northern California, a large health maintenance organization that introduced cotesting in 2003, we evaluated the cotesting results overall and by 5-year age groups. Women (n=580,289) who opted for and underwent cotesting (n cotests=812,598) between January 2003 and April 2008 were included in the analysis. Pap tests interpreted as atypical squamous cells of undetermined significance (ASC-US) or more severe were considered to be positive. Women were tested for carcinogenic HPV using an assay approved by the U.S. Food and Drug Administration. Binomial exact 95% confidence intervals (CIs) were calculated. RESULTS:: Overall, 6.27% (95% CI 6.21-6.32%) of cotests were carcinogenic HPV positive, and only 3.99% (95% CI 3.94-4.03%) cotests had normal cytology and were carcinogenic HPV positive. By comparison, 5.18% (95% CI 5.13-5.23%) of cotests had ASC-US or more severe cytology, and 2.87% (95% CI 2.84-2.91%) of cotests had ASC-US or more severe cytology and were carcinogenic HPV negative. CONCLUSION:: In a general screening population, concerns about excessive HPV test positives among women aged 30 years and older are not borne out.

UR - http://www.scopus.com/inward/record.url?scp=64249171907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249171907&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e3181996ffa

DO - 10.1097/AOG.0b013e3181996ffa

M3 - Article

VL - 113

SP - 595

EP - 600

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 3

ER -